Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mometasone furoate dry inhaler · 1 trial · 1 indication
FEV1 (forced expiratory volume in one second) measurement at the Baseline visit was compared to the FEV1 measurement during the last visit at Week 12. The mean percent change was calculated.
| Arm | Type | Description |
|---|---|---|
| MF-DPI | EXPERIMENTAL | MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) |
| BUD-DPI | ACTIVE_COMPARATOR | Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) |
| Name | Type | Description |
|---|---|---|
| mometasone furoate dry powder inhaler | DRUG | MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks. |
| Budesonide DPI | DRUG | Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks. |
Inclusion Criteria: * Subjects must be 12 years of age or older of either gender, who (and their parent/guardian if the subject is under the age of 20) must demonstrate their willingness to sign and write informed consent. * Subjects must have had a history of asthma for at least 6 months. * The su...
Mometasone furoate dry inhaler is an investigational small molecule being developed for the treatment of asthma. It is administered via a dry powder inhaler and is currently in Phase 3 clinical development. The drug is being studied in patients aged 12 years and older with asthma.
Mometasone furoate dry inhaler is being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol OGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with asthma.
Mometasone furoate dry inhaler is in Phase 3 clinical development for asthma. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, involving 180 participants, but the drug remains under clinical investigation.
Mometasone furoate dry inhaler has one completed Phase 3 clinical trial registered as NCT00442117, titled 'A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Asthmatics (Study P04880)'. The trial enrolled 180 participants aged 12 years and older with asthma and used an active control.
Mometasone furoate dry inhaler is a corticosteroid that works by reducing inflammation in the airways, which helps to improve asthma control. It is administered through a dry powder inhaler device, delivering the medication directly to the lungs to manage asthma symptoms.